Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

International severe asthma registry (ISAR): protocol for a global registry
J. Mark FitzGerald, Trung N. Tran, Marianna Alacqua, et al.
BMC Medical Research Methodology (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Eosinophilic and Noneosinophilic Asthma
Liam G. Heaney, Luis Pérez de Llano, Mona Al‐Ahmad, et al.
CHEST Journal (2021) Vol. 160, Iss. 3, pp. 814-830
Open Access | Times Cited: 179
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies
Susanne Hansen, Marianne Baastrup Soendergaard, Anna von Bülow, et al.
CHEST Journal (2023) Vol. 165, Iss. 2, pp. 253-266
Open Access | Times Cited: 44
Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults
Luis Pérez de Llano, Ghislaine Scélo, Trung N. Tran, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 7, pp. 869-880
Open Access | Times Cited: 25
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study
Andrew Menzies‐Gow, Claire McBrien, Bindhu Unni, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 63-78
Open Access | Times Cited: 68
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
Celeste Porsbjerg, Andrew Menzies‐Gow, Trung N. Tran, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 5, pp. 1202-1216.e23
Open Access | Times Cited: 39
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Michael E. Wechsler, Ghislaine Scélo, Désirée Larenas‐Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 262-272
Open Access | Times Cited: 24
Association between pre-biologic T2-Biomaker combinations and response to biologics in patients with severe asthma
Celeste Porsbjerg, Jonathan N. Townend, Céline Bergeron, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Exploring Definitions and Predictors of Response to Biologics for Severe Asthma
Ghislaine Scélo, Trung N. Tran, Tham Le, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 9, pp. 2347-2361
Open Access | Times Cited: 8
Costs of Oral Corticosteroid Use in Patients with Severe Asthma With/Without Chronic Rhinosinusitis with Nasal Polyps: Data from the Italian SANI Registry
Enrico Heffler, Francesco Blasi, Pierluigi Paggiaro, et al.
Advances in Therapy (2025) Vol. 42, Iss. 2, pp. 1196-1206
Open Access | Times Cited: 1
Potential Severe Asthma Hidden in UK Primary Care
Dermot Ryan, Heath Heatley, Liam G. Heaney, et al.
The Journal of Allergy and Clinical Immunology In Practice (2020) Vol. 9, Iss. 4, pp. 1612-1623.e9
Open Access | Times Cited: 53
Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
Ghislaine Scélo, Carlos A. Torres‐Duque, Jorge Máspero, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 1, pp. 42-53
Open Access | Times Cited: 21
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry
Wenjia Chen, Trung N. Tran, Mohsen Sadatsafavi, et al.
The Journal of Allergy and Clinical Immunology In Practice (2023) Vol. 11, Iss. 9, pp. 2732-2747
Open Access | Times Cited: 17
Comparative effectiveness of anti‐IL5 and anti‐IgE biologic classes in patients with severe asthma eligible for both
Paul Pfeffer, Nasloon Ali, Ruth Murray, et al.
Allergy (2023) Vol. 78, Iss. 7, pp. 1934-1948
Open Access | Times Cited: 15
International Variation in Severe Exacerbation Rates in Patients With Severe Asthma
Tae Yoon Lee, David Price, Chandra Prakash Yadav, et al.
CHEST Journal (2024) Vol. 166, Iss. 1, pp. 28-38
Closed Access | Times Cited: 4
Real-World Biologic Use Patterns in Severe Asthma, 2015–2021: The CLEAR Study
Trung N. Tran, Stephanie Chen, Benjamin Emmanuel, et al.
Pragmatic and Observational Research (2025) Vol. Volume 16, pp. 51-66
Open Access
Biologics in severe asthma: the role of real-world evidence from registries
Giovanni Paoletti, J. Pepys, Marta Casini, et al.
European Respiratory Review (2022) Vol. 31, Iss. 164, pp. 210278-210278
Open Access | Times Cited: 21
The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control
Stephanie Korn, Katrin Milger, Dirk Skowasch, et al.
Respiratory Medicine (2022) Vol. 195, pp. 106793-106793
Open Access | Times Cited: 20
Adult Severe Asthma Registries: A Global and Growing Inventory
Breda Cushen, Mariko Siyue Koh, Trung N. Tran, et al.
Pragmatic and Observational Research (2023) Vol. Volume 14, pp. 127-147
Open Access | Times Cited: 8
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy
Wenjia Chen, Mohsen Sadatsafavi, Trung N. Tran, et al.
Journal of Asthma and Allergy (2022) Vol. Volume 15, pp. 1491-1510
Open Access | Times Cited: 13
Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort
Eve Denton, Mark Hew, Matthew Peters, et al.
Allergy (2024) Vol. 79, Iss. 10, pp. 2700-2716
Open Access | Times Cited: 2
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017–2022: An Analysis of the International Severe Asthma Registry
Tham Le, David Price, Clement Erhard, et al.
Journal of Asthma and Allergy (2024) Vol. Volume 17, pp. 1055-1069
Open Access | Times Cited: 2
Real-World Experience on the Use of Mepolizumab from the Severe Asthma Registry of the German Asthma Net (MepoGAN-Study)
Stephanie Korn, Katrin Milger, Dirk Skowasch, et al.
Journal of Asthma and Allergy (2023) Vol. Volume 16, pp. 541-552
Open Access | Times Cited: 6
Serious fungal diseases in Democratic Republic of Congo – Incidence and prevalence estimates
Guyguy Kamwiziku, Jean-Claude Makangara-Cigolo, Emma Orefuwa, et al.
Mycoses (2021) Vol. 64, Iss. 10, pp. 1159-1169
Closed Access | Times Cited: 13
Comparison between clinical trials and real-world evidence studies on biologics for severe asthma
Francesco Menzella, Andrea Ballarin, Maria Cristina Sartor, et al.
Journal of International Medical Research (2022) Vol. 50, Iss. 11
Open Access | Times Cited: 9
Characteristics of severe asthma patients on biologics: a real-life European registry study
Stefania Principe, Levi B. Richards, Simone Hashimoto, et al.
ERJ Open Research (2023) Vol. 9, Iss. 3, pp. 00586-2022
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top